ONC vs. SVA, TH, AEZS, HBP, MDNA, MBX, FRX, EDT, HLS, and CRDL
Should you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Sernova (SVA), Theratechnologies (TH), Aeterna Zentaris (AEZS), Helix BioPharma (HBP), Medicenna Therapeutics (MDNA), Microbix Biosystems (MBX), Fennec Pharmaceuticals (FRX), Spectral Medical (EDT), HLS Therapeutics (HLS), and Cardiol Therapeutics (CRDL). These companies are all part of the "medical" sector.
Oncolytics Biotech (TSE:ONC) and Sernova (TSE:SVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends, community ranking and profitability.
Oncolytics Biotech has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Sernova has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.
Oncolytics Biotech received 188 more outperform votes than Sernova when rated by MarketBeat users. However, 88.89% of users gave Sernova an outperform vote while only 75.38% of users gave Oncolytics Biotech an outperform vote.
7.0% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 0.1% of Sernova shares are held by institutional investors. 6.2% of Oncolytics Biotech shares are held by company insiders. Comparatively, 14.5% of Sernova shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Oncolytics Biotech's return on equity of -102.66% beat Sernova's return on equity.
Oncolytics Biotech is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks.
Oncolytics Biotech presently has a consensus target price of C$6.00, suggesting a potential upside of 270.37%. Sernova has a consensus target price of C$1.50, suggesting a potential upside of 305.41%. Given Sernova's higher possible upside, analysts clearly believe Sernova is more favorable than Oncolytics Biotech.
In the previous week, Oncolytics Biotech and Oncolytics Biotech both had 2 articles in the media. Sernova's average media sentiment score of 0.07 beat Oncolytics Biotech's score of 0.00 indicating that Sernova is being referred to more favorably in the news media.
Summary
Oncolytics Biotech and Sernova tied by winning 7 of the 14 factors compared between the two stocks.
Get Oncolytics Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncolytics Biotech Competitors List
Related Companies and Tools
